Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Cell Biol Int ; 40(8): 917-25, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27296076

RESUMEN

Recent researches have reported the extensive pharmacological activities of Ginsenoside Rg1 including antioxidant, anti-inflammatory, and anticancer properties. Furthermore Rg1 was also shown to protect various kinds of cells from self-digestion by its anti-autophagy activity. In previous studies, angiotensin II (Ang II), a key mediator of renin-angiotensin system, has been demonstrated to contribute to the progression of renal injury including abnormal autophagy. However, whether Rg1 can relieve Ang II-induced autophagy in podocyte as well as the underlying molecular mechanism remains to be elucidated. Here, we employed Ang II-treated podocyte as a model to investigate the effect of Rg1 on autophagy and the involved signal pathways. In the present study, we found that Ang II strongly promoted autophagy in immortalized mouse podocyte cells by observing the formation of autophagosomes and detecting the expression of autophagic marker, for example, LC3-II. Notably, compared to the Ang II-treated cells, treatment with Rg1 significantly inhibited the formation of autophagosomes and expression of autophagy-related proteins in Ang II pre-treated podocyte. Meanwhile, Rg1 downregulated the activity of AMPK and GSK-3ß and upregulated the activity of P70S6K in Ang II-treated podocyte. In conclusion, these findings demonstrate that Ang II promotes autophagy in podocyte, and Rg1 effectively attenuates this process through AMPK/mTOR/PI3K pathway, suggesting that Rg1 may be beneficial to alleviate podocyte injury.


Asunto(s)
Proteínas Quinasas Activadas por AMP/metabolismo , Angiotensina II/metabolismo , Autofagia/efectos de los fármacos , Ginsenósidos/farmacología , Fosfatidilinositol 3-Quinasas/metabolismo , Podocitos/efectos de los fármacos , Serina-Treonina Quinasas TOR/metabolismo , Animales , Antioxidantes/farmacología , Apoptosis/efectos de los fármacos , Línea Celular , Regulación hacia Abajo/efectos de los fármacos , Ratones , Estrés Oxidativo/efectos de los fármacos , Fosforilación/efectos de los fármacos , Podocitos/citología , Especies Reactivas de Oxígeno/metabolismo , Transducción de Señal/efectos de los fármacos
2.
Med Sci Monit ; 22: 121-6, 2016 Jan 12.
Artículo en Inglés | MEDLINE | ID: mdl-26753766

RESUMEN

BACKGROUND: This study was performed to test the association between Helicobacter pylori (HP) and periodontal disease (PD). MATERIAL/METHODS: This was a case-control study in a comprehensive hospital, including all patients with newly diagnosed PD between 2012 and 2014 as cases and all patients without PD as controls, thorough periodontal examinations. Those who tested positive for HP were examined by means of polymerase chain reaction. Single and multivariate logistic regression was used to analyze the data using SPSS 19.0 software. RESULTS: This case-control study included 212 Han Chinese non-smoking adults. The results indicated that HP-positive status significantly increased the risk of PD (2.63 times higher (odds ratio [OR]=2.63; 95% confidence interval [CI]=1.48-4.67). After adjustment for age, sex, level of education, physical exercise, body mass index, and history of alcohol and diabetes mellitus, this association remained significantly (OR=2.82, 95% CI=1.55-5.13). CONCLUSIONS: PD might be associated with HP infection in adults and HP infection may be a significant and independent risk factor for PD.


Asunto(s)
Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/etnología , Helicobacter pylori , Enfermedades Periodontales/complicaciones , Enfermedades Periodontales/etnología , Adulto , Anciano , Anciano de 80 o más Años , Consumo de Bebidas Alcohólicas , Pueblo Asiatico , Estudios de Casos y Controles , China , Coinfección , Complicaciones de la Diabetes/etnología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Oportunidad Relativa , Enfermedades Periodontales/microbiología , Reacción en Cadena de la Polimerasa , Factores de Riesgo
3.
Acta Pharmacol Sin ; 36(2): 252-8, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25544361

RESUMEN

AIM: Interferon-γ inducible protein 16 (IFI16), a DNA sensor for DNA double-strand break (DSB), is expressed in most human hepatocellular carcinoma cell (HCC) lines. In this study we investigated the re-localization of chromatin-bound IFI16 by Nutlin-3, a DNA damage agent, in HCC cells in vitro, and the potential mechanisms. METHODS: Human HCC SMMC-7721 (wild-type TP53), Huh-7 (mutant TP53), Hep3B (null TP53) and normal fetal liver L02 cell lines were examined. DSB damage in HCC cells was detected via γH2AX expression and foci formation assay. The expression of IFI16 and IFNB mRNA was measured using RT-PCR, and subcellular localization and expression of the IFI16 protein were detected using chromatin fractionation, Western blot analysis, and fluorescence microscopy. RESULTS: Treatment of SMMC-7721 cells with Nutlin-3 (10 µmol/L) or etoposide (40 µmol/L) induced significant DSB damage. In SMMC-7721 cells, Nutlin-3 significantly increased the expression levels of IFI16 and IFNB mRNA, and partially redistributed chromatin-bound IFI16 protein to the cytoplasm. These effects were blocked by pretreatment with pifithrin-α, a p53 inhibitor. Furthermore, Nutlin-3 did not induce ectopic expression of IFI16 protein in Huh-7 and Hep3B cells. Moreover, the association of IFI16 with chromatin and Nutlin-3-induced changes in localization were not detected in L02 cells. CONCLUSION: Nutlin-3 regulates the subcellular localization of IFI16 in HCC cells in vitro in a p53-dependent manner.


Asunto(s)
Carcinoma Hepatocelular/metabolismo , Cromatina/metabolismo , Imidazoles/farmacología , Neoplasias Hepáticas/metabolismo , Proteínas Nucleares/metabolismo , Fosfoproteínas/metabolismo , Piperazinas/farmacología , Proteína p53 Supresora de Tumor/metabolismo , Línea Celular , Línea Celular Tumoral , Humanos
4.
Acta Pharmacol Sin ; 35(4): 513-22, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24632846

RESUMEN

AIM: Aldosterone is elevated in many diseases such as hypertension, diabetic nephropathy and chronic kidney disease, etc. The aim of this study was to investigate the effects of aldosterone on intracellular ROS production and autophagy in podocytes in vitro, and to explore the possibility of ginsenoside Rg1 (Rg1) being used for protecting podocytes from aldosterone-induced injury. METHODS: MPC5 mouse podocyte cells were tested. Autophagosome and autophagic vacuole formation were examined under confocal microscopy with MDC and acridine orange staining, respectively. ROS were detected with flow cytometry. Malondialdehyde content and superoxide dismutase (T-SOD) activity were measured using commercial kits. The expression of LC3-II, beclin-1, SOD2 and catalase was measured by Western blotting. RESULTS: Treatment with aldosterone (10 nmol/L) significantly increased ROS generation and the expression of SOD2 and catalase in MPC5 cells. Furthermore, treatment with aldosterone significantly increased the conversion of LC3-I to LC3-II, beclin-1 expression and autophagosome formation. Co-treatment with rapamycin (1 ng/mL) or chloroquine (10 µmol/L) further increased aldosterone-induced autophagosome formation. Co-treatment with Rg1 (80 ng/mL) effectively relieved oxidative stress and increased T-SOD activity at the early stage and subsequently decreased autophagy in aldosterone-treated podocytes. Co-treatment with 3-MA (4 mmol/L) or NAC (50 mmol/L) exerted similar effects against aldosterone-induced autophagy in podocytes. CONCLUSION: Aldosterone enhances ROS generation and promotes autophagy in podocytes in vitro. Ginsenoside-Rg1 effectively relieves aldosterone-induced oxidative stress, thereby indirectly inhibiting aldosterone-induced podocyte autophagy.


Asunto(s)
Aldosterona/toxicidad , Antioxidantes/farmacología , Ginsenósidos/farmacología , Podocitos/efectos de los fármacos , Animales , Proteínas Reguladoras de la Apoptosis/metabolismo , Autofagia/efectos de los fármacos , Beclina-1 , Catalasa/metabolismo , Línea Celular , Citoprotección , Malondialdehído/metabolismo , Ratones , Proteínas Asociadas a Microtúbulos/metabolismo , Podocitos/metabolismo , Podocitos/ultraestructura , Especies Reactivas de Oxígeno/metabolismo , Superóxido Dismutasa/metabolismo
5.
World J Clin Cases ; 10(13): 3989-4019, 2022 May 06.
Artículo en Inglés | MEDLINE | ID: mdl-35665115

RESUMEN

BACKGROUND: Metabolic reprogramming has been identified as a core hallmark of cancer. Solute carrier family 2 is a major glucose carrier family. It consists of 14 members, and we mainly study solute carrier family 2 member 1 (SLC2A1) and solute carrier family 2 member 2 (SLC2A2) here. SLC2A1, mainly existing in human erythrocytes, brain endothelial cells, and normal placenta, was found to be increased in hepatocellular carcinoma (HCC), while SLC2A2, the major transporter of the normal liver, was decreased in HCC. AIM: To identify if SLC2A1 and SLC2A2 were associated with immune infiltration in addition to participating in the metabolic reprogramming in HCC. METHODS: The expression levels of SLC2A1 and SLC2A2 were tested in HepG2 cells, HepG215 cells, and multiple databases. The clinical characteristics and survival data of SLC2A1 and SLC2A2 were examined by multiple databases. The correlation between SLC2A1 and SLC2A2 was analyzed by multiple databases. The functions and pathways in which SLC2A1, SLC2A2, and frequently altered neighbor genes were involved were discussed in String. Immune infiltration levels and immune marker genes associated with SLC2A1 and SLC2A2 were discussed from multiple databases. RESULTS: The expression level of SLC2A1 was up-regulated, but the expression level of SLC2A2 was down-regulated in HepG2 cells, HepG215 cells, and liver cancer patients. The expression levels of SLC2A1 and SLC2A2 were related to tumor volume, grade, and stage in HCC. Interestingly, the expression levels of SLC2A1 and SLC2A2 were negatively correlated. Further, high SLC2A1 expression and low SLC2A2 expression were linked to poor overall survival and relapse-free survival. SLC2A1, SLC2A2, and frequently altered neighbor genes played a major role in the occurrence and development of tumors. Notably, SLC2A1 was positively correlated with tumor immune infiltration, while SLC2A2 was negatively correlated with tumor immune infiltration. Particularly, SLC2A2 methylation was positively correlated with lymphocytes. CONCLUSION: SLC2A1 and SLC2A2 are independent therapeutic targets for HCC, and they are quintessential marker molecules for predicting and regulating the number and status of immune cells in HCC.

6.
Ying Yong Sheng Tai Xue Bao ; 27(4): 1163-1168, 2016 Apr 22.
Artículo en Zh | MEDLINE | ID: mdl-29732772

RESUMEN

To reduce the N2O emission from soil and enhance N utilization by crop, a field experiment was carried out to study the effects of nitrapyrin-N fertilizer application rates (0, 180, 270, 360 kg N·hm-2) on soil N2O emission and N apparent loss, grain yield and N utilization of summer maize. Results showed that the soil N2O emission under different N fertilizer treatments mainly occurred in periods from sowing to seedling, and from jointing to tasseling. Soil N2O emission peaks were observed after basal and top dressing events. Maize yield increased with N fertilizer rates but there was no significant difference between 270 and 360 kg N·hm-2, and the net income of these two treatments was 5209 and 5426 yuan·hm-2, respectively. Compared with no N fertilizer treatment, the N uptake in the N fertilizer treatments was increased by 109.6%-134.1%. The treatment of 270 kg N·hm-2 had the highest agronomic N efficiency and N use efficiency, but the N apparent loss was low. The treatment with nitrapyrin-N fertilization rate of 270 kg N·hm-2 appeared to be the optimal rate to obtain high maize yield and N use efficiency, and low soil N2O emission and N apparent loss.


Asunto(s)
Fertilizantes , Nitrógeno/metabolismo , Óxido Nitroso/metabolismo , Picolinas/metabolismo , Zea mays/metabolismo , Estaciones del Año , Suelo/química
7.
Exp Ther Med ; 12(5): 2965-2973, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27882102

RESUMEN

In order to evaluate the potential application value of cidofovir (CDV) in the prevention of human papillomavirus (HPV) infection and treatment of cervical cancer, the inhibitory effect of CDV on the proliferation of HPV 18-positive HeLa cells in cervical cancer was preliminarily investigated, using cisplatin (DDP) as a positive control. An MTT assay was used to analyze the effects of CDV and DDP on HeLa cell proliferation. In addition, clone formation assay and Giemsa staining were used to examine the extent of HeLa cell apoptosis caused by CDV and DDP. Flow cytometry was also used to detect the shape and size of apoptotic cells following propidium iodide staining, while western blot analysis identified the expression levels of of E6 and p53 proteins in HeLa cells. A cell climbing immunofluorescence technique was used to locate the subcellular position of p53 in HeLa cells. The results demonstrated that CDV and DDP inhibited the proliferation of HeLa cells in a concentration- and time-dependent manner. Flow cytometry showed that CDV and DDP treatments resulted in cell arrest in the S-phase, and triggered programmed cell death. Furthermore, western blot analysis revealed that CDV and DDP inhibited E6 protein expression and activated p53 expression in HeLa cells. Finally, the immunofluorescence results indicated that CDV and DDP inhibited the nuclear export of p53 by E6 protein, which is required for degradation of endogenous p53 by MDM2 and human papilloma virus E6. In conclusion, CDV and DDP inhibited HeLa cell proliferation in a concentration- and time-dependent manner, reduced the expression of E6 protein, and reinstated p53 protein activity. Thus, CDV regulates cell cycle arrest and apoptosis, and may be a potential cervical cancer therapeutic strategy.

8.
Pathog Dis ; 73(5)2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25846576

RESUMEN

Chronic gastric infection by the Gram-negative bacterium Helicobacter pylori (H. pylori) is strongly associated with gastritis, gastric ulcer and the development of distal gastric carcinoma and gastric mucosal lymphoma in humans. Antibiotic treatment of H. pylori is becoming less effective because of increasing antibiotic resistance; other treatment approaches such as specifically targeted methods, etc. to destroy this organism would be beneficial. An epitope vaccine is a promising option for protection against H. pylori infection. In this study, a multi-epitope vaccine was constructed by linking cholera toxin B subunit (CTB), two antigenic fragments of H. pylori urease I subunit (UreI20-29, UreI98-107) and four antigenic fragments of H. pylori urease B subunit (UreB12-23, UreB229-251, UreB327-400, UreB515-561), resulting in the recombinant CTB-UreI-UreB (BIB). Its protective effect against H. pylori infection was evaluated in BALB/c mice. Significant protection against H. pylori challenge was achieved in BALB/c mice immunized with BIB (15/18, 83.3%), rIB plus rCTB (6/18, 33.3%) and rIB (2/18, 11.1%) separately, while no protective effect was found in the mice immunized with either adjuvant rCTB alone or PBS. The induction of significant protection against H. pylori is possibly mediated by specific serum IgA and mucosal sIgA antibodies, and a mixed Th1/Th2/Th17 cells response. This multi-epitope vaccine might be a promising vaccine candidate that helps to control H. pylori infection.


Asunto(s)
Vacunas Bacterianas/inmunología , Infecciones por Helicobacter/prevención & control , Helicobacter pylori/inmunología , Ureasa/inmunología , Adyuvantes Inmunológicos/genética , Administración Oral , Animales , Anticuerpos Antibacterianos/análisis , Anticuerpos Antibacterianos/sangre , Vacunas Bacterianas/administración & dosificación , Toxina del Cólera/genética , Modelos Animales de Enfermedad , Epítopos/genética , Epítopos/inmunología , Femenino , Helicobacter pylori/genética , Inmunoglobulina A/análisis , Inmunoglobulina A/sangre , Masculino , Ratones Endogámicos BALB C , Proteínas Recombinantes de Fusión , Linfocitos T/inmunología , Ureasa/genética , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunología
9.
J Biomater Appl ; 28(1): 12-9, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22274876

RESUMEN

In this study, the biocompatibility and bone regeneration performance of nano-hydroxyapatite/collagen/poly(L-lactide) (nHAC/PLA) and nano-hydroxyapatite/collagen/calcium sulfate hemihydrate (nHAC/CSH) as bone-filling materials were evaluated and compared in a critical box-shaped defect model in the mandible of the rabbits. In vivo results indicated that there was significant difference in early bone remodeling between two types of bone substitutes. nHAC/PLA has shown excellent biocompatibility, but no adequate handling properties. The addition of CSH to nHAC provided better manipulability compared to nHAC/PLA. Furthermore, nHAC/CSH possesses superior properties in restoring critical-sized bone defects of maxillofacial region at the early stage of remodeling over nHAC/PLA. Our results suggested that nHAC/CSH could be an alternative to the conventionally used bone tissue engineering materials.


Asunto(s)
Sustitutos de Huesos/química , Trasplante Óseo/métodos , Osteogénesis , Animales , Regeneración Ósea , Calcificación Fisiológica , Sulfato de Calcio , Colágeno , Durapatita , Masculino , Ensayo de Materiales , Microscopía Electrónica de Rastreo , Nanoestructuras/química , Nanoestructuras/ultraestructura , Poliésteres , Conejos , Ingeniería de Tejidos , Difracción de Rayos X
10.
Interface Focus ; 2(3): 387-92, 2012 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-23741614

RESUMEN

More and more applications of nanomaterials have been achieved in the biomedicine field. Numerous nanomedical devices, such as bone grafts with nano-hydroxyapatite and the silver-based anti-bacteria products, have been developed and have been trying to enter into the Chinese market. The State Food and Drug Administration of China (SFDA) is facing a critical challenge of how to explore and supervise the safety assessment of the nanomedical products. This paper briefly introduces the approval status of nanomedical products and the current advances of the safety assessment of nanomaterials in China.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA